Literature DB >> 26879035

Targeted delivery of etoposide to cancer cells by folate-modified nanostructured lipid drug delivery system.

Shumei Zhang1, Caixia Lu2, Xiaoli Zhang3, Junsheng Li1, Hong Jiang1.   

Abstract

CONTEXT: Cardiotoxicity and myelosuppression of etoposide (ETP) limited its clinical application. Targeted drug delivery system could deliver anticancer agents to the target cancerous cells, thus reducing their toxicity.
OBJECTIVE: In this study, folate (FA) was applied for the construction of nanostructured lipid carriers (NLCs), and used for targeted delivery of ETP to tumors overexpresses the FA receptors.
METHODS: FA-poly (ethylene glycol)-distearoylphosphatidylethanolamine was synthesized. FA decorated and ETP-loaded NLCs (FA-ETP-NLCs) were prepared and the formulation was optimized by Box-Behnken design. Their particle size (PS), zeta potential and drug encapsulation efficiency (EE) was evaluated. In vitro cytotoxicity studies of FA-ETP-NLCs were tested in CT26, SGC7901, NCI-H209 cell lines. In vivo antitumor efficacies of the carriers were evaluated on mice bearing CT26 cells xenografts.
RESULTS: The optimum FA-ETP-NLCs formulations had a PS of 120.86 nm. The growth of CT26, SGC790 or NCI-H209 cells in vitro was obviously inhibited. FA-ETP-NLCs also displayed the best antitumor activity than other formulations in vivo.
CONCLUSION: The results demonstrated that FA-ETP-NLCs were efficient in selective delivery to CT26, SGC790 or NCI-H209 cells overexpressing the FA receptors. Also, FA-ETP-NLCs can sufficiently transfer ETP to the cancer cells, enhance the antitumor capacity. Thus, FA-ETP-NLCs could prove to be a superior nanomedicine to achieve tumor therapeutic efficacy.

Entities:  

Keywords:  Box–Behnken design; etoposide; folic acid; nanostructured lipid carriers; tumor target

Mesh:

Substances:

Year:  2016        PMID: 26879035     DOI: 10.3109/10717544.2016.1141258

Source DB:  PubMed          Journal:  Drug Deliv        ISSN: 1071-7544            Impact factor:   6.419


  6 in total

1.  Novel CD123-aptamer-originated targeted drug trains for selectively delivering cytotoxic agent to tumor cells in acute myeloid leukemia theranostics.

Authors:  Haibin Wu; Meng Wang; Bo Dai; Yanmin Zhang; Ying Yang; Qiao Li; Mingyue Duan; Xi Zhang; Xiaomei Wang; Anmao Li; Liyu Zhang
Journal:  Drug Deliv       Date:  2017-11       Impact factor: 6.419

2.  Characterization and antitumor efficacy of poly(L-lactid acid)-based etoposide-loaded implants.

Authors:  Li Gao; Chuanqi Xie; Yuzhi Du; Xiaodong Wang; Erkang Xuan; Xiuxiu Liu; Yang Zhao; Jianjian Xu; Lan Luo
Journal:  Drug Deliv       Date:  2017-11       Impact factor: 6.419

Review 3.  Common Chemical Inductors of Replication Stress:  Focus on Cell-Based Studies.

Authors:  Eva Vesela; Katarina Chroma; Zsofia Turi; Martin Mistrik
Journal:  Biomolecules       Date:  2017-02-21

Review 4.  Antineoplastics Encapsulated in Nanostructured Lipid Carriers.

Authors:  Gustavo Henrique Rodrigues da Silva; Ludmilla David de Moura; Fabíola Vieira de Carvalho; Gabriela Geronimo; Talita Cesarim Mendonça; Fernando Freitas de Lima; Eneida de Paula
Journal:  Molecules       Date:  2021-11-17       Impact factor: 4.411

5.  Controlled gene and drug release from a liposomal delivery platform triggered by X-ray radiation.

Authors:  Wei Deng; Wenjie Chen; Sandhya Clement; Anna Guller; Zhenjun Zhao; Alexander Engel; Ewa M Goldys
Journal:  Nat Commun       Date:  2018-07-13       Impact factor: 14.919

Review 6.  Solid Lipid Nanoparticles and Nanostructured Lipid Carriers as Smart Drug Delivery Systems in the Treatment of Glioblastoma Multiforme.

Authors:  Raneem Jnaidi; António José Almeida; Lídia M Gonçalves
Journal:  Pharmaceutics       Date:  2020-09-10       Impact factor: 6.321

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.